Literature DB >> 22475869

Nutritional Management of Phenylketonuria.

Erin L Macleod1, Denise M Ney.   

Abstract

Phenylketonuria (PKU) is caused by deficient activity of the enzyme phenylalanine hydroxylase, needed to convert the essential amino acid (AA) phenylalanine (phe) to tyrosine. In order to prevent neurological damage, lifelong adherence to a low-phe diet that is restricted in natural foods and requires ingestion of a phe-free AA formula to meet protein needs is required. The goal of nutritional management for those with PKU is to maintain plasma phe concentrations that support optimal growth, development, and mental functioning while providing a nutritionally complete diet. This paper reviews developing a lifelong dietary prescription for those with PKU, outcomes of nutritional management, compliance with the low-phe diet across the life cycle, and new options for nutritional management. An individualized dietary prescription is needed to meet nutrient requirements, and the adequacy of phe intake is monitored with assessment of blood phe levels. Elevated phe concentrations may occur due to illness, excessive or inadequate phe intake, or inadequate intake of AA formula. Although normal growth and development occurs with adherence to the low-phe diet, it is important to monitor vitamin, mineral and essential fatty acid status, especially in those who do not consume sufficient AA formula. Given the growing population of adults with PKU, further research is needed to understand the risks for developing osteoporosis and cardiovascular disease. There are promising new options to liberalize the diet and improve metabolic control such as tetrahydrobiopterin therapy or supplementation with large neutral AAs. Moreover, foods made with glycomacropeptide, an intact protein that contains minimal phe, improves the PKU diet by offering a palatable alternative to AA formula. In summary, continued efforts are needed to overcome the biggest challenge to living with PKU - lifelong adherence to the low-phe diet.

Entities:  

Year:  2010        PMID: 22475869      PMCID: PMC2901905          DOI: 10.1159/000312813

Source DB:  PubMed          Journal:  Ann Nestle Eng        ISSN: 0517-8606


  63 in total

1.  Biochemical effects of supplemented long-chain polyunsaturated fatty acids in hyperphenylalaninemia.

Authors:  C Agostoni; S Scaglioni; M Bonvissuto; M G Bruzzese; M Giovannini; E Riva
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2001-02       Impact factor: 4.006

Review 2.  [Management of phenylketonuria and hyperphenylalaninemia: the French guidelines].

Authors:  V Abadie; J Berthelot; F Feillet; N Maurin; A Mercier; H Ogier de Baulny; L de Parscau
Journal:  Arch Pediatr       Date:  2005-05       Impact factor: 1.180

3.  Phenylalanine requirement in children with classical PKU determined by indicator amino acid oxidation.

Authors:  Glenda Courtney-Martin; Rachelle Bross; Mahroukh Raffi; Joe T R Clarke; Ronald O Ball; Paul B Pencharz
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-12       Impact factor: 4.310

4.  Tyrosine requirements in children with classical PKU determined by indicator amino acid oxidation.

Authors:  R Bross; R O Ball; J T Clarke; P B Pencharz
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-02       Impact factor: 4.310

5.  Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria.

Authors:  Erin L MacLeod; Murray K Clayton; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2010-04-14       Impact factor: 4.797

6.  Taste preferences and feeding behaviour in children with phenylketonuria on a semisynthetic diet.

Authors:  M Owada; K Aoki; T Kitagawa
Journal:  Eur J Pediatr       Date:  2000-11       Impact factor: 3.183

7.  Nutrient intake and food consumption of adolescents and young adults with phenylketonuria.

Authors:  B Schulz; H J Bremer
Journal:  Acta Paediatr       Date:  1995-07       Impact factor: 2.299

8.  Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care.

Authors:  Carol S Camfield; Marissa Joseph; Teresa Hurley; Karen Campbell; Susan Sanderson; Peter R Camfield
Journal:  J Pediatr       Date:  2004-07       Impact factor: 4.406

9.  Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria.

Authors:  Betina Fiege; Nenad Blau
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

10.  PKU-what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders.

Authors:  F J van Spronsen; K Kiaer Ahring; M Gizewska
Journal:  J Inherit Metab Dis       Date:  2009-01-13       Impact factor: 4.982

View more
  35 in total

1.  New insights in growth of phenylketonuric patients.

Authors:  María L Couce; Ipek Guler; Andrés Anca-Couce; Marta Lojo; Alicia Mirás; Rosaura Leis; Alejandro Pérez-Muñuzuri; José M Fraga; Francisco Gude
Journal:  Eur J Pediatr       Date:  2014-11-01       Impact factor: 3.183

2.  Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria.

Authors:  Denise M Ney; Sangita G Murali; Bridget M Stroup; Nivedita Nair; Emily A Sawin; Fran Rohr; Harvey L Levy
Journal:  Mol Genet Metab       Date:  2017-04-06       Impact factor: 4.797

3.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

Review 4.  Emerging issues in public health genomics.

Authors:  Dana Dolinoy; Beth Tarini; J Scott Roberts
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

Review 5.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

Review 6.  Current situation and prospects of newborn screening and treatment for Phenylketonuria in China - compared with the current situation in the United States, UK and Japan.

Authors:  Lin Mei; Peipei Song; Norihiro Kokudo; Lingzhong Xu; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2013-11

7.  Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.

Authors:  Patrick Solverson; Sangita G Murali; Adam S Brinkman; David W Nelson; Murray K Clayton; Chi-Liang Eric Yen; Denise M Ney
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-31       Impact factor: 4.310

8.  Effect of ultrafiltered milk permeate and non-dairy creamer powder concentration on low phenylalanine yoghurt's physicochemical properties during storage.

Authors:  Parisa Goldar; Mohammad Hadi Givianrad; Akbar Shams
Journal:  J Food Sci Technol       Date:  2016-08-13       Impact factor: 2.701

9.  Relationships Between Childhood Experiences and Adulthood Outcomes in Women with PKU: A Qualitative Analysis.

Authors:  Rachel M Roberts; Tamara Muller; Annabel Sweeney; Drago Bratkovic; Anne Gannoni; Brianna Morante
Journal:  JIMD Rep       Date:  2016-06-14

Review 10.  Nutritional treatment for inborn errors of metabolism: indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example.

Authors:  Kathryn M Camp; Michele A Lloyd-Puryear; Kathleen L Huntington
Journal:  Mol Genet Metab       Date:  2012-07-16       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.